VX17-659-102: A Phase 3, Randomized, Double-blind, Contr

Project: Research project

Project Details

Description

VX17-659-102: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
StatusFinished
Effective start/end date4/12/183/12/20

Funding

  • Vertex Pharmaceuticals Incorporated

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.